RPS27L抗体

+ +

•  

   

     Gel: 12%SDS-PAGE, Lysate: 40 μg, Lane 1-3: Mouse adrenal gland tissue, Rat lung tissue, 231 cell lysates, Primary antibody: P09803(RPS27L Antibody) at dilution 1/400, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 10 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P09803(RPS27L Antibody) at dilution 1/55. (Original magnification: ×200)    

  
  

The RPS27L (Ribosomal Protein S27-like) antibody is a valuable tool for studying the role of the RPS27L protein, a member of the ribosomal protein S27 family. RPS27L shares homology with the small ribosomal subunit protein S27 but has distinct regulatory functions beyond ribosome biogenesis. It is implicated in cellular stress responses, DNA repair, and apoptosis, particularly through its interaction with the tumor suppressor p53. Studies suggest that RPS27L stabilizes p53 by binding to MDM2. a key negative regulator of p53. thereby enhancing p53-mediated transcriptional activity in response to DNA damage. This interaction positions RPS27L as a potential modulator of cell cycle arrest and apoptosis in cancer biology.

The RPS27L antibody is widely used in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to detect protein expression levels, subcellular localization, and tissue-specific distribution. It aids in exploring RPS27L's differential expression in tumors, its role in chemoresistance, and its prognostic value in cancers such as colorectal and hepatocellular carcinoma. Researchers also utilize this antibody to investigate crosstalk between ribosomal proteins and stress-response pathways. Commercial RPS27L antibodies are typically raised in rabbits or mice, targeting specific epitopes within the protein's conserved regions. Validation includes reactivity assays and knockout cell line controls to ensure specificity. Its applications span basic research on ribosome-mediated signaling and translational studies targeting cancer therapeutics.